Giesel F L, Sterzing F, Schlemmer H P, Holland-Letz T, Mier W, Rius M, Afshar-Oromieh A, Kopka K, Debus J, Haberkorn U, Kratochwil C
Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Unit of Radiopharmaceutic Chemistry, German Cancer Research Center, Heidelberg, Germany.
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1400-6. doi: 10.1007/s00259-016-3346-0. Epub 2016 Mar 14.
Multi-parametric magnetic resonance imaging (MP-MRI) is currently the most comprehensive work up for non-invasive primary tumor staging of prostate cancer (PCa). Prostate-specific membrane antigen (PSMA)-Positron emission tomography-computed tomography (PET/CT) is presented to be a highly promising new technique for N- and M-staging in recurrent PCa-patients. The actual investigation analyses the potential of (68)Ga-PSMA11-PET/CT to assess the extent of primary prostate cancer by intra-individual comparison to MP-MRI.
In a retrospective study, ten patients with primary PCa underwent MP-MRI and PSMA-PET/CT for initial staging. All tumors were proven histopathological by biopsy. Image analysis was done in a quantitative (SUVmax) and qualitative (blinded read) fashion based on PI-RADS. The PI-RADS schema was then translated into a 3D-matrix and the euclidian distance of this coordinate system was used to quantify the extend of agreement.
Both MP-MRI and PSMA-PET/CT presented a good allocation of the PCa, which was also in concordance to the tumor location validated in eight-segment resolution by biopsy. An Isocontour of 50 % SUVmax in PSMA-PET resulted in visually concordant tumor extension in comparison to MP-MRI (T2w and DWI). For 89.4 % of sections containing a tumor according to MP-MRI, the tumor was also identified in total or near-total agreement (euclidian distance ≤1) by PSMA-PET. Vice versa for 96.8 % of the sections identified as tumor bearing by PSMA-PET the tumor was also found in total or near-total agreement by MP-MRI.
PSMA-PET/CT and MP-MRI correlated well with regard to tumor allocation in patients with a high pre-test probability for large tumors. Further research will be needed to evaluate its value in challenging situation such as prostatitis or after repeated negative biopsies.
多参数磁共振成像(MP-MRI)目前是前列腺癌(PCa)非侵入性原发性肿瘤分期最全面的检查方法。前列腺特异性膜抗原(PSMA)正电子发射断层扫描-计算机断层扫描(PET/CT)被认为是复发性PCa患者N分期和M分期极具前景的新技术。本研究通过与MP-MRI进行个体内比较,分析(68)Ga-PSMA11-PET/CT评估原发性前列腺癌范围的潜力。
在一项回顾性研究中,10例原发性PCa患者接受了MP-MRI和PSMA-PET/CT进行初始分期。所有肿瘤均经活检病理证实。基于前列腺影像报告和数据系统(PI-RADS)以定量(SUVmax)和定性(盲法读片)方式进行图像分析。然后将PI-RADS模式转换为三维矩阵,并使用该坐标系的欧几里得距离来量化一致性程度。
MP-MRI和PSMA-PET/CT对PCa的定位均良好,这也与活检在八分区分辨率下验证的肿瘤位置一致。与MP-MRI(T2加权像和扩散加权成像)相比,PSMA-PET中50%SUVmax的等轮廓线在视觉上显示肿瘤范围一致。根据MP-MRI,89.4%含有肿瘤的切片,PSMA-PET也能全部或几乎完全一致(欧几里得距离≤1)地识别出肿瘤。反之,PSMA-PET识别为有肿瘤的切片中,96.8%也能被MP-MRI全部或几乎完全一致地发现肿瘤。
对于大肿瘤预测试概率高的患者,PSMA-PET/CT和MP-MRI在肿瘤定位方面相关性良好。在前列腺炎或多次活检阴性等具有挑战性的情况下,评估其价值还需要进一步研究。